Clinical Trials Logo

Clinical Trial Summary

Nowadays there is a strong interest in optimising human health through manipulation of non-digestible carbohydrates (NDC). NDC can be used as substrates by gut microbiota, which results in NDC degradation, production of fermentation products, such as short-chain fatty acids (SCFA), and a shift in microbiome composition and activity. It is hypothesized that SCFAs mediate parts of the beneficial effects of NDC. In mice, the influx of SCFA into the host correlated strongly with improvements of markers of the metabolic syndrome, in contrast to the concentrations of SCFA in the proximal colon. Therefore, the influx of short chain fatty acids (SCFA) into the body may be of high importance in improving metabolism. There is a need for more studies in humans to trace the life course of SCFA and their regulatory role in human metabolism. To study this inner world of bacterial products in humans, we will use a nasal-intestine catheter that can be used for delivery of components and sampling chyme in the proximal colon. Before the proposed methodology can be applied in a large intervention study, a small scale feasibility study needs to be performed that addresses colonic placement of the nasal-intestine cathether and colonic sampling of regular and NDC-enriched chyme samples. We will investigate the acute fermentation of fructo- and galacto-oligosaccharides in the proximal colon. Moreover, we will deliver 13C-labelled SCFA via a naso-intestinal catheter to quantify the fluxes of SCFA production, interconversion and uptake by the host. A small-scale, 7-day parallel feasibility trial, N=5 subjects will receive GOS/FOS supplements (mix 1:1 ratio, 15 gram/day), and N=5 other subjects will receive placebo supplements (isocaloric maltodextrin, 12 gram/day). At the last day of the supplementation period, the catheter will be placed, and afterwards participants stay maximum 5 hours in the hospital, to ensure progression of the nose-intestine catheter. After an overnight fast, subjects will visit the hospital again for measurements. Subjects will consume a NDC bolus (200 mL tap water, 5 gram fructo-oligosaccharides, 5 gram galacto-oligosaccharides, non-absorbable marker (PEG-4000). Afterwards, they are not allowed to eat for 6.5 hours. Isotopically 13C-labelled SCFAs will be delivered in the proximal colon. Blood and colonic luminal samples, breath samples, faeces and urine will be collected.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04499183
Study type Interventional
Source Wageningen University
Contact MARA VAN TRIJP
Phone 0317 484 067
Email mara.vantrijp@wur.nl
Status Recruiting
Phase N/A
Start date October 8, 2020
Completion date February 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT05726435 - Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players N/A
Completed NCT05634044 - Validating eNose Measurement of Daily Fiber Intake N/A
Completed NCT03848546 - Stimulating Fiber Intake Via Personalized Dietary Advice N/A
Completed NCT04013607 - Fiber Fermentation Kinetics Inside the Gut, and Utilization of Bacterial Metabolites N/A
Withdrawn NCT04438473 - Pectin Supplemented Enteral Feedings in Critically Ill Patients N/A
Completed NCT04352231 - Luxembourgish Fiber Cohort N/A
Completed NCT03387345 - Barley and Rice Mixture Effects on Blood Glucose N/A
Recruiting NCT04690075 - Effect of Dietary Fiber on Metabolism, Inflammation and Nutritional Status in Patients With Chronic Diseases N/A
Completed NCT03796286 - A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses N/A
Recruiting NCT04611217 - Dietary Fiber Effects on the Microbiome and Satiety N/A
Completed NCT01321736 - Gut Health Response to Dietary Fiber N/A